KLRG1 and neoplasm: Interestingly, the Vax/aGITR/aPD-1 therapy resulted in a ~2-fold increase in the frequency of tumor-infiltrating KLRG1+CD8+ effector cells and KLRG1+CD8+Tet+ cells, compared to all other groups (Figure 6B-6C), inferring that Ag-specific KLRG1+CD8+ effector cells can traffic to the tumor site to elicit rapid effector function.